Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer

Darvishi, Behrad; Farahmand, Leila; Majidzadeh‐A, Keivan

doi:10.1016/j.omtn.2017.03.007

Cited by 46 publications

(38 citation statements)

References 140 publications

(227 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, in an attempt to make a clinically relevant formulation and to test if the delivery agent influences the functionality of RNA fibers, we chose mesoporous silica‐based nanoparticles (MSNs) as an alternative non‐lipid carrier. MSNs have demonstrated tremendous potential for delivering active pharmaceuticals and TNAs targeting numerous diseases. Versatility of this delivery platform relies on MSNs' high surface area, tunable surface chemistry, biocompatibility, and well‐defined structure of pores.…”

Section: Resultsmentioning

confidence: 99%

RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition

Rackley

Stewart

Salotti

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

RNA is a versatile biomaterial that can be used to engineer nanoassemblies for personalized treatment of various diseases. Despite promising advancements, the design of RNA nanoassemblies with minimal recognition by the immune system remains a major challenge. Here, an approach is reported to engineer RNA fibrous structures to operate as a customizable platform for efficient coordination of siRNAs and for maintaining low immunostimulation. Functional RNA fibers are studied in silico and their formation is confirmed by various experimental techniques and visualized by atomic force microscopy (AFM). It is demonstrated that the RNA fibers offer multiple advantages among which are: i) programmability and modular design that allow for simultaneous controlled delivery of multiple siRNAs and fluorophores, ii) reduced immunostimulation when compared to other programmable RNA nanoassemblies, and iii) simple production protocol for endotoxin-free fibers with the option of their cotranscriptional assembly. Furthermore, it is shown that functional RNA fibers can be efficiently delivered with various organic and inorganic carriers while retaining their structural integrity in cells. Specific gene silencing triggered by RNA fibers is assessed in human breast cancer and melanoma cell lines, with the confirmed ability of functional fibers to selectively target single nucleotide mutations.

show abstract

Section: Resultsmentioning

confidence: 99%

RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition

Rackley

Stewart

Salotti

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…Generally, positively charged MSNs are uptaken by liver cells and excreted in the feces through the hepatobiliary excretion pathway. Whereas, negatively charged MSNs accumulate in the Kuppfer cells of liver without metabolization resulting in hepatotoxicity . Under physiological conditions, many forms of MSNs can dissolve into soluble silica, which can be excreted in urine as silicic acid or oligomeric silica compounds …”

Section: Elimination Of Degradable Msnsmentioning

confidence: 99%

Multidisciplinary Role of Mesoporous Silica Nanoparticles in Brain Regeneration and Cancers: From Crossing the Blood–Brain Barrier to Treatment

Mendiratta

Hussein

Nasser

et al. 2019

Part & Part Syst Charact

View full text Add to dashboard Cite

that by 2040, neurodegenerative diseases will surpass cancer as the second reason of death after cardiovascular diseases in such aged populations. [1,2] As per a 2017 report, neurological diseases cost the United States of America about $800 billion annually and this number is expected to increase even further over the coming years as the percentage of aged citizens increases. [3] Unlike most other major diseases, the pace of drug development and delivery in case of neurodegenerative diseases has been stationary, partially due to lack of biomarkers that can diagnose such diseases long before the neurological symptoms arise and the challenges associated with identification of targets for drugs that can terminate or minimize neurodegeneration. Most importantly, delivering new cerebral therapeutic agents is impeded by the extensive and robust blood-brain barrier (BBB) which prevents the vast majority of drugs from crossing to the brain after systemic administration. During brain infections, intracerebral hemorrhage, or in neurodegenerative disorders, the BBB is altered in such a way that it allows easy access of inflammatory inducing molecules that may cause adverse neuronal damage. [4] Given the importance of early diagnosis and treatment of neurodegenerative diseases, new drug delivery technologies have appeared in the last decade.As shown in Scheme 1, unique nanomaterials have been reported and several nanosized drug delivery systems including liposomes, dendrimers, carbon nanotubes (CNTs), inorganic and hybrid nanoparticles, and polymeric micelles have gained attention and have been tested for targeted drug delivery not only for neurodegenerative diseases but also for several other ailments. [5][6][7][8][9][10] The discovery of MCM-41 was recognized as a major breakthrough in materials science and since then mesoporous silica nanoparticles (MSNs), thanks to their superior physiochemical properties such as large porosity, high surface areas, low toxicity, controllable sizes, and wide range of morphologies compared to conventional nanoparticles (NPs) have emerged as favorable tools in biomedical applications as nanocarriers for encapsulation and delivery of therapeutic medicines. [11][12][13][14] Designing biocompatible MSNs and their multifunctional derivatives for drug transport as well as theranostics is one of the hottest areas of research in the field of nanobiotechnology and nanomedicine. [15][16][17][18][19] High loading capacity, acceptable biocompatibility, and limitless possibilities of surface functionalization for specific cellular recognition Mesoporous silica nanoparticles (MSNs) have gained wide attention for their role in biomedicine and as drug delivery vehicles. Their structural tunability, high surface area, and easy functionalization impart significant advantages over conventional materials. In this Review, recent advances in the synthesis, drug delivery, and therapeutic roles of MSNs in the treatment of various neurodegenerative and neuroinflammatory diseases are presented. The intention is to...

show abstract

“…Externally coated MSNs with a layer of lipid or polyethylene glycol make them ideal carriers for successful treatment of cancer. (Darvishi et al, 2017) Drug Targeting to molecular level in TNBC Inhibition of TNBC metastasis requires therapeutic targeting to the level of the molecules. The molecular therapy varies the activity of programmed overexpressed receptors, proteins, hormones or changes the mechanisms for DNA repair.…”

Section: Therapy With Mesoporous Silica Nanoparticles (Msns)mentioning

confidence: 99%

Triple-negative breast cancer: challenges and treatment options

Shekar

Mallya

Gowda

et al. 2020

ijrps

View full text Add to dashboard Cite

TNBCs or Triple negative breast cancers are characterized by the deficiency of progesterone and estrogen receptors and also the absence down regulation of Human epithelial growth receptor type 2 (HER2). TNBCs have low prognosis rate because of heterogeneity.The heterogeneous nature of this cancer has constrained the effective progress in drug targeting among certain people.. In general HER2, PR and ER and the rate of proliferation are main predictive and prognostic factors in the detection of cancer of breast.Several pathways are involved in the progression of triple negative breast cancer from basal like cancer cells. The foremost being the loss by BRCA1-mediated pathway or mutation in the expression of several receptors.Certain groups have made some progress in unwinding TNBC's biological diversity and relating patterns of gene expression to molecular or genotypic subtypes.Earlier molecular categories of breast cancer use PAM50 via gene expression analysis to separate the breast cancer into the 4 intrinsic subtypes classified among many TNBCs in basal (BL) group and others divided between HER2 and luminal rich group. Currently, targeted therapy for TNBCs has not been approved. Nonetheless, a continuous progress has been made to detect the tumors at specific site for targeting and establish novel improved therapy.This review speaks about different approaches to TNBC treatment like cytotoxic therapy, targeted strategies, and chemotherapeutics by damage to DNA and targeting for repair of DNA and potent Nano carriers for targeting TNBC.

show abstract

Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer

Cited by 46 publications

References 140 publications

RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition

RNA Fibers as Optimized Nanoscaffolds for siRNA Coordination and Reduced Immunological Recognition

Multidisciplinary Role of Mesoporous Silica Nanoparticles in Brain Regeneration and Cancers: From Crossing the Blood–Brain Barrier to Treatment

Triple-negative breast cancer: challenges and treatment options

Contact Info

Product

Resources

About